See more : Kimbell Royalty Partners, LP (KRP) Income Statement Analysis – Financial Results
Complete financial analysis of Syndax Pharmaceuticals, Inc. (SNDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Syndax Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Harbour Centre Development Limited (0051.HK) Income Statement Analysis – Financial Results
- Thales S.A. (THLEF) Income Statement Analysis – Financial Results
- CrossFirst Bankshares, Inc. (CFB) Income Statement Analysis – Financial Results
- UpSnap, Inc. (CEENF) Income Statement Analysis – Financial Results
- S. Pack & Print Public Company Limited (SPACK.BK) Income Statement Analysis – Financial Results
Syndax Pharmaceuticals, Inc. (SNDX)
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 139.71M | 1.52M | 1.52M | 1.52M | 2.11M | 1.22M | 627.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 12.00K | 454.00K | 456.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 51.00K |
| Gross Profit | -12.00K | -454.00K | 139.25M | 1.52M | 1.52M | 1.52M | 2.11M | 1.22M | 627.00K | 0.00 | 0.00 | 0.00 | -51.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 99.67% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 163.02M | 118.50M | 88.25M | 50.44M | 42.99M | 60.11M | 48.20M | 31.67M | 9.55M | 10.18M | 3.21M | 5.24M | 6.09M |
| General & Administrative | 0.00 | 33.26M | 25.24M | 22.51M | 16.06M | 17.29M | 15.86M | 13.32M | 11.59M | 11.16M | 5.36M | 3.49M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 66.92M | 33.26M | 25.24M | 22.51M | 16.06M | 17.29M | 15.86M | 13.32M | 11.59M | 11.16M | 5.36M | 3.49M | 3.49M |
| Other Expenses | 0.00 | 2.42M | -1.29M | -1.74M | 1.49M | 1.92M | 1.15M | -706.00K | -37.00K | 4.00K | -3.01M | -1.00K | 0.00 |
| Operating Expenses | 229.95M | 151.76M | 113.49M | 72.94M | 59.06M | 77.39M | 64.06M | 44.99M | 21.14M | 21.33M | 8.57M | 8.73M | 9.57M |
| Cost & Expenses | 229.95M | 151.76M | 113.49M | 72.94M | 59.06M | 77.39M | 64.06M | 44.99M | 21.14M | 21.33M | 8.57M | 8.73M | 9.62M |
| Interest Income | 21.16M | 5.87M | 403.00K | 841.00K | 1.57M | 0.00 | 0.00 | 0.00 | 161.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 208.00K | 3.14M | 1.90M | 2.36M | 1.57M | 1.94M | 1.42M | 956.00K | 1.58M | 0.00 | 0.00 | 0.00 | 1.99M |
| Depreciation & Amortization | 12.00K | 454.00K | 456.00K | 515.00K | 451.00K | 78.00K | 76.00K | 89.00K | 21.00K | 15.00K | 13.00K | 34.00K | 51.00K |
| EBITDA | -229.94M | -151.76M | 27.28M | -70.29M | -55.60M | -73.88M | -61.88M | -43.68M | -20.49M | -21.32M | -8.56M | -5.26M | -11.05M |
| EBITDA Ratio | 0.00% | 0.00% | 18.77% | -4,708.17% | -3,792.95% | -5,001.71% | -2,938.99% | -3,587.38% | -3,248.48% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -229.95M | -151.76M | 26.22M | -71.42M | -57.54M | -75.88M | -61.95M | -43.77M | -20.51M | -21.33M | -8.57M | -8.73M | -9.62M |
| Operating Income Ratio | 0.00% | 0.00% | 18.77% | -4,708.17% | -3,792.95% | -5,001.71% | -2,938.99% | -3,587.38% | -3,271.61% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 20.59M | 2.42M | -1.29M | -1.74M | 1.49M | 1.92M | 1.15M | -706.00K | -3.61M | 1.50M | -5.60M | -1.23M | -3.47M |
| Income Before Tax | -209.36M | -149.34M | 24.93M | -73.16M | -56.05M | -73.96M | -60.80M | -44.47M | -24.12M | -19.83M | -14.17M | -9.97M | -13.09M |
| Income Before Tax Ratio | 0.00% | 0.00% | 17.84% | -4,822.54% | -3,694.59% | -4,875.48% | -2,884.35% | -3,645.25% | -3,846.73% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -5.59M | -43.00K | -89.00K | -92.00K | 1.92M | -76.00K | -89.00K | 1.54M | -1.50M | 2.59M | 1.23M | 0.00 |
| Net Income | -209.36M | -143.75M | 24.93M | -73.07M | -55.96M | -73.96M | -60.80M | -44.47M | -24.12M | -19.83M | -14.17M | -9.97M | -13.09M |
| Net Income Ratio | 0.00% | 0.00% | 17.84% | -4,816.68% | -3,688.53% | -4,875.48% | -2,884.35% | -3,645.25% | -3,846.73% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.98 | -2.37 | 0.48 | -1.77 | -1.84 | -2.92 | -2.90 | -3.04 | -1.39 | -2.07 | -1.77 | -0.14 | -21.11 |
| EPS Diluted | -2.98 | -2.37 | 0.46 | -1.77 | -1.84 | -2.92 | -2.90 | -3.04 | -1.39 | -2.07 | -1.77 | -0.14 | -21.11 |
| Weighted Avg Shares Out | 70.26M | 60.76M | 52.06M | 41.31M | 30.49M | 25.37M | 21.00M | 14.62M | 17.37M | 9.60M | 8.01M | 70.28M | 619.96K |
| Weighted Avg Shares Out (Dil) | 70.37M | 60.76M | 53.62M | 41.31M | 30.49M | 25.37M | 21.00M | 14.62M | 17.37M | 9.60M | 8.01M | 70.28M | 619.96K |
Recent Price Trend in Syndax (SNDX) is Your Friend, Here's Why
Syndax (SNDX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Syndax (SNDX) Is a Great Choice for 'Trend' Investors, Here's Why
Syndax (SNDX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Are You Looking for a Top Momentum Pick? Why Syndax Pharmaceuticals (SNDX) is a Great Choice
Does Syndax Pharmaceuticals (SNDX) have what it takes to be a top stock pick for momentum investors? Let's find out.
ETON Up as FDA Accepts NDA for Dehydrated Alcohol Injection
Eton (ETON) gains as the its new drug application (NDA) for dehydrated alcohol injection for methanol poisoning is accepted for review by the FDA.
VERA Dips Despite Positive Data From IgA Nephropathy Study
VERA posts positive top-line data from the phase IIb ORIGIN study evaluating atacicept for the treatment of IgA nephropathy.
Here's Why Momentum in Syndax (SNDX) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Syndax (SNDX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
ACER Down Despite FDA Nod for Urea Cycle Disorders Drug
The FDA approves Acer Therapeutics' (ACER) Olpruva (sodium phenylbutyrate) to treat certain patients with urea cycle disorders. Share price falls 33.3% following the announcement.
4 Top Biotech Stocks Worth Adding to Your Portfolio in 2023
New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, GSK, IMCR and SNDX well amid the volatility.
Syndax Pharmaceuticals: Today's Best Nearby Biotech Cap-Gain Prospect
How informed are you about binding interactions of Menin with the mixed lineage leukemia 1 protein for the treatment of acute myeloid leukemia? Neither am I. This analysis has been supported by the Institutional Investing community who has the resources...
Syndax's (SNDX) Leukemia Drug Gets FDA Breakthrough Therapy Tag
The FDA bestows a Breakthrough Therapy designation to Syndax's (SNDX) revumenib for treating patients with relapsed/refractory acute leukemia harboring a KMT2A rearrangement. Stock up.
Source: https://incomestatements.info
Category: Stock Reports